Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

10.1002/ijc.33822

Saved in:
Bibliographic Details
Main Authors: Huang, Yiqing, Soon, Yu Yang, Aminkeng, Folefac, Tay, Sen Hee, Ang, Yvonne, Kee, Adrian CL, Goh, Boon Cher, Wong, Alvin SC, Soo, Ross A
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Article
Language:English
Published: WILEY 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
immune checkpoint inhibitors
immune-related adverse events
nonsmall cell lung cancer
CHECKPOINT INHIBITORS
CHEMOTHERAPY
PEMBROLIZUMAB
IPILIMUMAB
NIVOLUMAB
TOXICITY
ASSOCIATION
CARBOPLATIN
COMBINATION
BLOCKADE
Online Access:https://scholarbank.nus.edu.sg/handle/10635/235038
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/235038

Similar Items